Background/Aims: Combination treatment consisting of hepatic arterial infusion chemotherapy with epirubicin and cisplatin (HAIC-EC) and systemic infusion of low-dose 5-fluorouracil (5-FU) are sometimes effective against advanced hepatocellular carcinoma (HCC). However, there is no effective treatment for advanced HCCs with arterioportal shunts (APS) or arteriovenous shunts (AVS). Methods: We investigated a response and adverse events of a new combination protocol of repeated HAIC-EC and percutaneous intratumoral injection chemotherapy with a mixture of recombinant interferon-gamma (IFN-γ) and 5-FU (PIC-IF) in patients with far-advanced HCCs with large APSs or AVSs. Results: There was a complete response (CR) for the large vascular shunts in all three patients and for all tumor burdens in two patients. Significant side effects were flu-like symptoms (grade 2) and bone marrow suppression (grade 2 or 3) after each cycle, but these were well-tolerated. 
INTRODUCTION
Hepatocellular carcinoma (HCC) is the 5th most common malignancy worldwide and the 3rd most common cause of cancer mortality. 1 Because a majority of patients present at an advanced stage, which does not consistently respond to any chemotherapeutic protocols, the prognosis of HCC is generally very poor. Only a small proportion of cases with HCC diagnosed at an early stage as a result of close surveillance, and with serial imaging studies, could be eligible for and receive curative treatments, such as liver transplantation and surgical resection, resulting in a favorable long-term outcome. 2 The Barcelona Clinic Liver Cancer (BCLC) staging classification system, which reflects liver functional status and characteristic features of HCC staging, is a clinically useful algorithm for selecting proper management and predicting the prognosis of HCC patients. 2, 3 The management of patients with advanced BCLC stages (BCLC stage C) is a complex issue, as the degree of vascular invasion, tumor size and number, extrahepatic metastasis, HCC-associated complications, liver functional reserve, and the performance status of the patient must be taken into account. Systemic chemotherapy, radiation therapy, and transarterial infusion chemotherapy via implantable drug delivery systems rarely offer survival benefits, such as select patients with well-preserved liver function and a good performance status. 4 Despite a search for an effective multidisciplinary approach to improve outcomes, no treatment protocol has been developed for patients with advanced BCLC stages and major vascular invasions and/or extrahepatic metastasis.
It 
MATERIALS AND METHODS

Eligibility
The eligibility criteria for chemotherapy were as follows: (1) 18-75 years of age; (2) 
Patients
Of the HCC patients admitted to our hospital between 
Treatment protocol
The treatment protocol, consisted of one cycle of The length of admission was usually from 4-7 days.
Laboratory tests were usually performed 3 times during the admission (before and 1 day after treatment, and prior to discharge). Additional laboratory tests were performed from 7-10 days after discharge in the outpatient clinic to evaluate Each clinical course is described in detail below (Table 1) .
Patient 1
A 60-year-old man was admitted due to variceal bleeding.
Dynamic CT scan showed a massive infiltrative type of HCC with a maximum diameter ≥12 cm and the main portal vein tumor thrombosis with a massive APS in the right lobe.
The baseline blood tests were as follows: white blood cell count (WBC) 17,100/mm 3 , hemoglobin 6.2 g/dL, platelet count 217,000/mm (Fig. 1, 2 ).
Patient 2
A 67-year-old man, who had experienced exertional Co. Ltd, Seoul Korea), both serological HCC biomarkers normalized again (Fig. 3) . The patient is alive without any An ill-defined huge mass mainly involving the right lobe (white arrow) and tumor thrombosis along the right portal system (black arrow) and inferior vena cava were markedly decreased after treatment. Pulmonary metastatic lesions had also completely disappeared (dotted arrow). Hepatic arteriography (C, before treatment; D, after treatment) showed an ill-defined huge mass mainly involving the right lobe and tumor thrombosis along the right portal system and inferior vena cava, together with a large APS at the time of initial treatment. All of the lesions had markedly improved after the treatment.
evidence of recurrence after 28 months (DFI, 18 months).
Patient 3
A 66-year-old man who had anorexia and nausea Intrahepatic HCC lesions with a large AVS showed a complete response to the treatment protocol, but extrahepatic metastatic lesions showed only a partial response early in the treatment course. However, elevation of the AFP and PIVKA-II levels and multiple metastases in both lungs and adrenal gland were aggravated without intrahepatic recurrence of HCC late in the treatment course. 
DISCUSSION
In patients with far advanced HCC complicated by major portal vein tumor thrombosis, the prognosis is dismal, and if not treated, the overall survival is 3.5 months. 
